An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00721981

Enrollment

120

Registered

2008-07-25

Start date

2009-04-30

Completion date

2009-10-31

Last updated

2010-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Non-small Cell Lung Cancer

Keywords

patient preference, oncology, chemotherapy, NSCLC

Brief summary

The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours * Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment) * Patients who are in transition from first to second line treatment * Patients who signed an informed consent

Exclusion criteria

* Chemotherapy naïve patients * Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy) * Patients who ever had chemotherapy for an indication other than NSCLC

Design outcomes

Primary

Measure	Time frame
To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment	once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy

Secondary

Measure	Time frame
current medical practice treatment objectives and modalities side effects	once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy
socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences	once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy

Countries

Germany

Outcome results